Programs

Home/Programs

Day 1 : Mar 29,2025
Day 1
Agenda Download
Keynote Speakers
Biography:
Prof. Ali Soofastaei is a seasoned expert in artificial intelligence and data analytics, with a rich background in transforming industries through innovative technological solutions. Currently the CEO of Innovative AI and an academic editor for "Advanced Analytics for Industry 4.0," Ali has over a decade of experience in applying AI-driven methodologies to optimize processes and enhance decision-making in fields such as mining, manufacturing, and healthcare. His recent projects include pioneering work on digital twins, predictive analytics, and decarbonization in industrial settings. With a passion for data-driven storytelling, Ali is an advocate for the sustainable and ethical use of AI in critical industries, particularly in healthcare, where he focuses on personalized care and operational efficiency. A thought leader in his field, Ali is also an active keynote speaker at international conferences, where he shares insights on the intersection of AI, biosciences, and sustainability.

Abstract:
The healthcare industry stands at a pivotal juncture where artificial intelligence (AI) and data analytics are transforming every facet of patient care, from diagnostics to treatment and beyond. This presentation will explore the profound role of AI-driven predictive analytics in shaping a more sustainable and patient-centered healthcare system. By integrating vast amounts of real-time patient data with advanced machine learning models, predictive analytics enables healthcare providers to identify patterns, anticipate patient needs, and personalize treatments with unprecedented accuracy. This talk will highlight the critical applications of AI in early disease detection, population health management, and personalized treatment planning. Key examples will illustrate how predictive models are being used to monitor chronic diseases, prevent adverse health events, and streamline clinical workflows, thus ensuring that healthcare resources are allocated efficiently and patient outcomes are optimized. The session will also address the unique challenges of implementing AI in healthcare, including data privacy, ethical concerns, and integration with existing healthcare infrastructure. Additionally, it will emphasize the importance of sustainable AI practices, focusing on reducing the carbon footprint of AI models and advocating for energy-efficient algorithms. By discussing the intersection of AI technology with bioscience advancements, this presentation aims to provide attendees with actionable insights into leveraging predictive analytics to create a more resilient, accessible, and sustainable healthcare ecosystem. Attendees will leave equipped with a deeper understanding of how AI can empower healthcare providers and policymakers to create a future where medical care is not only innovative but also equitable and sustainable.
Speaker Sessions
Biography:
Dr. Roshanak T. Semnani is an executive director, overseeing the Translational Research at Precigen, Inc. based in Maryland, USA.  She has her Ph.D. in Immunology from the University of Chicago and was at NIH prior to joining the company in 2018. She is an experienced multi-disciplinary senior executive with extensive expertise in the field of infectious disease, autoimmunity, and immuno-oncology along with drug development in Cell and Gene therapy, from preclinical to Immunological studies for clinical trials. Her experience involves combining basic and translational research for further understanding of the mechanisms of disease to develop strategies for which enable organizations to achieve their goals.   In addition, she serves on multiple Scientific Committees, and she is active as a reviewer for leading journals.

Abstract:
Recurrent Respiratory Papillomatosis (RRP) is a rare, neoplastic disorder caused by chronic infection with Human Papillomavirus (HPV) type 6 or 11. RRP is characterized by growth of benign tumors (papillomas) in the upper aerodigestive tract, leading to significant morbidity due to airway obstruction and although rare, RRP has the potential for transformation to dysplasia or malignant cancer. The standard-of-care for RRP is frequent ablative procedures and currently there are no approved therapeutics. It is common for patients to require multiple surgeries to keep the breathing passage open. However, these frequent surgeries can lead to irreversible laryngotracheal scarring and disability, emphasizing the need for transformative new non-surgical treatment modalities. PRGN-2012 is a gorilla adenovirus-based gene therapy/immunotherapy designed to generate HPV6/11-specific T cell immunity in RRP patients. Phase 1 of our ongoing pivotal trial (NCT04724980) evaluates the safety and efficacy of PRGN-2012 in patients with RRP requiring a minimum of 3 surgeries in the 12 months prior to treatment. Patients received 4 subcutaneous (SQ) injections of PRGN-2012 over 12 weeks. The results from the 15 patients demonstrated that PRGN-2012 treatment was safe and well-tolerated and resulted in clinically significant benefit with a 50% rate of complete response. In Phase 2 portion of the pivotal study an additional 23 patients were treated at dose level 2. Our data indicated that the administration of PRGN2012 led to the development of systemic HPV-specific T cell response with a higher magnitude in responders as compared to nonresponses. Furthermore, neutralizing antibody (Nab) titer against gorilla adenovectors remained low in majority of patients after vaccine administration and no apparent correlation between NAb incidence or titer and clinical response was observed.
Biography:
Dr. Ioannidis is currently an Assistant Professor of Surgery in the Medical School of Aristotle University of Thessaloniki. He studied medicine in the Aristotle University of Thessaloniki and graduated at 2005. He received his MSC in “Medical Research Methodology” in 2008 from Aristotle University of Thessaloniki and in “Surgery of Liver, Biliary Tree and Pancreas” from the Democritus University of Thrace in 2016. He received his PhD degree in 2014 from the Aristotle University of Thessaloniki as valedictorian for his thesis “The effect of combined administration of omega-3 and omega-6 fatty acids in ulcerative colitis. Experimental study in rats.” He is a General Surgeon with special interest in laparoscopic surgery and surgical oncology and also in surgical infections, acute care surgery, nutrition and ERAS and vascular access. He has received fellowships for EAES, ESSO, EPC, ESCP and ACS and has published more than 180 articles with more than 3000 citations and an H-index of 28
Abstract: 
Acute peritonitis is a relatively common intra-abdominal infection that a general surgeon will have to manage many times in his surgical carrier. Usually it is a secondary peritonitis caused either by direct peritoneal invasion from an inflamed infected viscera or by gastrointestinal tract integrity loss. The mainstay of treatment is source control of the infection which is in most cases surgical. In the physiologically deranged patient there is indication for source control surgery in order to restore the patient’s physiology and not the patient anatomy utilizing a step approach and allowing the patient to resuscitate in the intensive care unit. In such cases there is a clear indication for relaparotomy and the most common strategy applied is open abdomen. In the open abdomen technique the fascial edges are not approximated and a temporarily closure technique is used. In such cases the negative pressure wound therapy seems to be the most favourable technique, as especially in combination with fascial traction either by sutures or by mesh gives the best results regarding delayed definite fascial closure, and morbidity and mortality. In our surgical practice we utilize in most cases the use of negative pressure wound therapy with a temporary mesh placement. In the initial laparotomy the mesh is placed to approximate the fascial edges as much as possible without whoever causing abdominal hypertension and in every relaparotomy the mesh is divided in the middle and, after the end of the relaparotomy and dressing change, is approximated as much as possible in order for the fascial edges to be further approximated. In every relaparotomy the mesh is further reduced to finally allow definite closure of the aponeurosis. In the presence of ostomies the negative pressure wound therapy can be applied as usual taking care just to place the dressing around the stoma and the negative pressure can be the standard of -125 mmHg. However, in the presence of anastomosis the available date are scarce and the possible strategies are to differ the anastomosis for the relaparotomy with definitive closure and no further need of negative pressure wound therapy, to low the pressure to -25 mmHg in order to protect the anastomosis and to place the anastomosis with omentum in order to avoid direct contact to the dressing. The objective should be early closure, within 7 days, of the open abdomen to reduce mortality and complications. 
Biography:
Prof. Islam Al-Dababsekh is a distinguished medical professional and researcher specializing in regenerative medicine, genetics, and stem cell therapies. As the Director of I.D. Stem Cells and Genome Institute and founder of I.D. Medical Group, he combines clinical expertise with innovative research to pioneer advancements in stem cell-based treatments. With a Ph.D. in cardiovascular surgery and professorship in genetics, Prof. Al-Dababsekh’s career spans over two decades. His diverse medical expertise includes general, vascular, and endovascular surgery, as well as dermatology. He has contributed significantly to the field through clinical practice, groundbreaking patents, and international presentations. A member of ISSCR and other prestigious associations, he has been at the forefront of regenerative medicine since 2017, focusing on cutting-edge therapies to enhance human health. Prof. Al-Dababsekh’s commitment to advancing science is reflected in his leadership roles, research, and dedication to improving patient outcomes worldwide.

Abstract:
Introduction:
Infertility is a prevalent concern globally, with male infertility, including conditions like azoospermia, posing significant challenges. Conventional treatments are limited, prompting interest in stem cell therapies. In the MENA region, high infertility rates underscore the need for accessible treatments. This study explores using MSCs to generate spermatocytes, potentially revolutionizing male infertility treatments by leveraging advancements in stem cell technology. 

Literature Review:
The study builds on global research exploring stem cell solutions for infertility. Unlike studies on animal tissues or specific germ cells, our focus on human-derived MSCs bridges critical gaps in applicability. Previous studies on SSCs and BM-SCs highlight their potential but underscore challenges in scalability and clinical translation, contrasting with our approach using readily available MSCs. 

Materials and Methods:
MSCs were mobilized from bone marrow using granulocyte colony-stimulating factor (G-CSF) and differentiated in vitro under controlled conditions. Key markers of meiosis progression such as DMC1, DAZL, Oct-4 were monitored, culminating in the development of functional spermatocytes suitable for IVF attempts. Results The study successfully differentiated MSCs into mature spermatocytes capable of fertilizing oocytes. Outcomes included viable embryos developed from fertilized oocytes and preserved for future use, highlighting the efficacy of MSC-derived gametes in reproductive technologies. 

Discussion:
Compared to conventional approaches focusing on SSCs or animal-derived stem cells, our study introduces MSCs as a versatile source for generating functional gametes. This approach addresses practical limitations associated with existing methods and opens new avenues for personalized infertility treatments. 

Conclusion:
This study demonstrates MSCs' potential to revolutionize male infertility treatments by producing functional spermatocytes. Further optimization and clinical validation are crucial to enhance the efficacy of MSC-based therapies, offering new hope to individuals and couples globally affected by infertility.
Biography:
Mr. Mark Jeembs M. Pineda is a dedicated professional currently pursuing a Master’s degree in Health Professions Education at the University of the Philippines Manila. He serves as a Professor II at Centro Escolar University, teaching Research in the Health Sciences and Medical-Surgical Nursing to third- and fourth-year nursing students. His academic role allows him to shape the next generation of healthcare professionals with a strong emphasis on research and evidence-based practice. In addition to his academic responsibilities, Mr. Pineda works as a Public Health Nurse II at Tondo Medical Center, where he applies his clinical expertise to improve patient care. His interests primarily focus on infection control, patient safety, and Basic Emergency, Obstetrics,  and Newborn Care. These areas reflect his commitment to enhancing health outcomes in the community and promoting best practices in nursing. Mr. Pineda is actively engaged in research related to his specialty, contributing valuable insights to the fields of public health and nursing education. His work aims to address critical issues in healthcare, ultimately fostering safer and more effective patient care environments. Through his dual roles in academia and clinical practice, Mr. Pineda exemplifies the integration of education and service, making a meaningful impact on his students and the patients he serves.

Abstract
Introduction:
Effective leadership is essential in healthcare, significantly impacting organizational performance and patient outcomes. Strong leaders foster team collaboration, improve communication, and drive continuous improvement, ultimately enhancing patient care. Leadership development is critical as healthcare systems grow increasingly complex, requiring skills to navigate challenges such as technological advancements and evolving patient needs. Despite its importance, leadership development often receives limited attention in healthcare. This study aimed to evaluate the impact of a structured coaching program based on the ADDIE (Analysis, Design, Development, Implementation, Evaluation) model on leadership competencies among personnel at Tondo Medical Center. The study's findings contribute to bridging the gap in leadership development strategies within healthcare institutions.
Methods:
A quasi-experimental design was utilized, with pre-and post-test assessments to measure leadership development. The study was conducted in the selected department at Tondo Medical Center, purposively selected for its relevance. Participants were randomly assigned to experimental (n = 34) and control (n = 24) groups. The experimental group completed a structured coaching intervention, which included interactive workshops, one-on-one coaching, and group discussions, while the control group did not. The program focused on enhancing self-awareness, knowledge, and leadership behaviors. Data were analyzed using descriptive statistics, normality tests, and the Wilcoxon Signed-Rank Test to assess the program’s effectiveness.
Results:
Post-test evaluations demonstrated significant improvements in the experimental group. Self-awareness increased from 2.9 to 4.86 (Z = -4.88, p < 0.05), while leadership skills improved from 2.9 to 4.96 (Z = -4.92, p < 0.05). Knowledge and behavior also showed marked gains, confirmed by statistically significant changes (p < 0.05). In contrast, the control group exhibited minimal improvements, with slight changes in leadership skills (Z = -2.01, p = 0.04) and no significant differences in other variables.
Discussion:
The findings highlight the effectiveness of structured coaching programs in enhancing leadership competencies, confidence, and professional growth. Participants rated the program highly, with a mean score of 4.91 (SD = 0.27). Recommendations include expanding the program, integrating advanced content, conducting long-term evaluations, and applying it to other healthcare settings.
Biography:
Fahd Nasr is a professor specializing in Molecular Genetics and Functional Genomics at the Faculty of Sciences, Lebanese University. He earned his PhD in Molecular Genetics and Cell Biology from Pierre and Marie Curie Paris VI University and has completed extensive postdoctoral training in yeast genetics and molecular biology. With a focus on Saccharomyces cerevisiae as a model organism, Prof. Nasr's research spans the genomic and post-genomic eras, examining the molecular mechanisms underlying cell cycle regulation and their implications in tumorigenesis. Prof. Nasr has been a member of the Lebanese Association for the Advancement of Science since 2000 and has significantly contributed to Lebanon’s higher education system, designing joint Master’s and postgraduate courses, such as "Yeast Genetics and Molecular Biology" and "Translational Biology." His educational philosophy centers on student empowerment through critical thinking, inquiry, and ethical responsibility, preparing students to address global challenges like biodiversity loss, climate change, and emerging pathogens.

Abstract:
Fahd Nasr is a professor specializing in Molecular Genetics and Functional Genomics at the Faculty of Sciences, Lebanese University. He earned his PhD in Molecular Genetics and Cell Biology from Pierre and Marie Curie Paris VI University and has completed extensive postdoctoral training in yeast genetics and molecular biology. With a focus on Saccharomyces cerevisiae as a model organism, Prof. Nasr's research spans the genomic and post-genomic eras, examining the molecular mechanisms underlying cell cycle regulation and their implications in tumorigenesis. Prof. Nasr has been a member of the Lebanese Association for the Advancement of Science since 2000 and has significantly contributed to Lebanon’s higher education system, designing joint Master’s and postgraduate courses, such as "Yeast Genetics and Molecular Biology" and "Translational Biology." His educational philosophy centers on student empowerment through critical thinking, inquiry, and ethical responsibility, preparing students to address global challenges like biodiversity loss, climate change, and emerging pathogens.
Biography:
Giuseppe Recchia  graduated in Medicine and Surgery at University of Padua-I and carried out research at  Hospital of Verona-I and Downstate Medical Center, NYC-USA. He have been for several years Medical and Scientific Director in the Italian R&D centre of a major multinational pharmaceutical group. He is co-founder and CEO of daVinci Digital Therapeutics (2019-2023), daVi DigitalMedicine (2021-present) and Digital Rehab (2021-present), startups of digital therapeutics and care supports. Also he is co-leading the R&D process of a candidate digital therapeutic for chronic insomnia with University of Verona-I, a candidate digital therapeutic for high blood pressure with Polifarma, Rome-I and a candidate digital therapeutic for motor rehabilitation, all currently in clinical development, and he is a vice-president of Trends in Health and Healthcare, a not for profit organization for the development of innovation in healthcare. He has been teaching the course ‘Digital Health & Therapeutics’ at the University of Tor Vergata, Rome-I since 2020.

Abstract:
The current model of chronic disease management - centralised and intermittent - is unsustainable and inadequate to meet patients' needs. In order to overcome this model, it is necessary to ensure the regular monitoring of the patient, in the context of day-to-day life, promoting disease self-management, personalising treatment and, above all, fostering patient empowerment. Today, patient-facing digital health technologies can enable this evolution. These are digital applications based on apps and other devices, used directly by the patient as part of a therapeutic plan shared with the doctor. According to a 2023 new classification, they have different purposes, such as monitoring (Patient Monitoring), self-management (Care Supports), diagnosis (Digital Diagnositcs) and therapy (Digital Therapeutics). In most cases, they are certified devices, for which clinical evidence is often required. Among the different categories of digital patient-facing health technologies, digital therapeutics have received the most attention and generated the most interest. Defined by the ISO TR1147/2023 as ‘health software intended to treat or alleviate a disease, disorder, condition, or injury by generating and delivering a medical intervention that has a demonstrable positive therapeutic impact on a patient's health’, they are indicated for the treatment of several diseases, such as mental, metabolic, neurological and others. The medical intervention delivered by the software may already be available in the literature (e.g. cognitive-behavioural therapy for insomnia) or may be developed de novo (e.g. for hypertension). Demonstrating a positive health outcome requires a similar clinical development as the drug, based on both pilot and confirmatory clinical trials. Digital therapeutics are prescription interventions (although they are also present as OTC), already in use in several countries. The application of artificial intelligence systems will increase the therapeutic potential of digital therapeutics and the first examples are already available. For their full adoption in medical practice, however, it is necessary to manage and overcome several barriers, such as data ownership, patient trust, literacy and access, integration into clinical care and reimbursement. 
Biography:
David Wortley is CEO & Founder of 360in360 Immersive Experiences and a VP of the International Society of Digital Medicine (ISDM). He is a Fellow of the Royal Society of Arts and Commerce and a global thought leader and innovator on enabling technologies for health, education and the environment. He is on the editorial board of the Digital Medicine Journal. He is an Associate Member of the Royal Society of Medicine and a Visiting Fellow at the Faculty of Health and Social Sciences at Bournemouth University. As the Founding Director of the Serious Games Institute (SGI) at Coventry University, his team established an International Centre of Excellence for Applied Research and Innovation in the field of serious games and immersive technologies for a wide range of applications. His areas of special interest are technologies for preventative healthcare, collaboration, virtual reality and interactive rich media knowledge sharing. He a professional virtual event facilitator, webinar host and publisher.
Abstract:
The integration of artificial intelligence (AI) and disruptive technologies is transforming the healthcare landscape, profoundly influencing nursing practice. This presentation explores the evolving role of nurses in a technologically advanced healthcare ecosystem, examining how AI and other innovations are reshaping patient care, decision-making, and professional workflows. AI-powered tools, such as predictive analytics and clinical decision support systems, enable nurses to provide more personalized and efficient care by identifying patient risks, streamlining diagnoses, and enhancing treatment planning. Simultaneously, robotic systems and wearable health technologies are revolutionizing monitoring, mobility assistance, and chronic disease management, allowing nurses to allocate more time to critical human-centered aspects of care. However, the adoption of these technologies introduces challenges, including ethical considerations, data security concerns, and the need for continuous upskilling. This session will discuss strategies to prepare nurses for these changes, emphasizing the importance of digital literacy, interdisciplinary collaboration, and resilience in adapting to a rapidly changing work environment. By fostering a forward-thinking approach, this presentation aims to inspire nurses to embrace innovation while maintaining their pivotal role as patient advocates and caregivers, ensuring that technology enhances—not replaces—the human connection at the heart of nursing.
Biography:
Dr Abhaya Gupta trained in India then moved abroad after his postgraduate MD degree. He has extensive experience of managing acute medical and elderly Medicine issues at hospitals in India, Middle East and UK. He  is currently  working as Consultant Medicine and Care of Elderly since last 20 years at a teaching hospital in United Kingdom. He is a teacher and trainer for junior doctors/ nursing and multidisciplinary team members,  examiner for Cardiff Medical School . He also is practising  Acute Clinical Physician in hospital. He  has specialist expertise and experience in Orthogeriatrics. He  commenced and leads specialist osteoporosis service at UK hospital, had first patient on Injection Romosozumab in Wales. He was a pioneer at commencing Acute Collaborative Orthogeriatrician led Acute Hip Unit since 2011 for patients with Hip Fractures- first of its kind in Wales,UK  - a unique award winning service. He is Editorial Board member of ‘Geriatric Medicine’ , reviewer of ‘Age and Ageing’ journal and member of local specialist societies. He has published widely in several peer reviewed journals, presented his research as posters at several national and International meetings and conferences. He has published a book ‘Measurement scales in Elderly Medicine’. He is member of GOSI (Geriatric Orthopaedic Society of India) and has been invited as speaker at GOSICON and GERICON conferences. His main hobby is helping his Psychiatrist wife in house gardening jobs.
Abstract:
Objective: To identify the level of knowledge, attitude, and practice (KAP) toward osteoporosis amongst nurses and medical students at a teaching hospital in United Kingdom.
Methods: A cross-sectional design was adopted in this study. A convenience sample of 150  trained nurses  working in medical and orthopaedic wards and 150 medical students (Year 4 and 5) were  given a self administered questionnaire. The assessment tool used in the current study contained 35 items, measuring KAP amongst a cohort of teaching hospital nurses and students toward osteoporosis. Part 1-demographic details. Part 2 –knowledge amongst participants. Part 3 attitudes towards osteoporosis  Part 4- their practice. The correlation Pearson test and regression test were used to analyze data using Statistical Package for Social Sciences.
Results: The total KAP scores were 25, 38, and 20 respectively amongst nurses and 45, 58 and 65 amongst medical students. These results revealed that  nurses have a moderate level of KAP toward osteoporosis with better scores amongst medical students.
 Conclusions:  nurses who regularly deal with high risk osteoporosis patients showed a moderate KAP and had major gaps on knowledge, their attitudes and clinical practice towards osteoporosis. Their training and education needs to be improved as an effective step to reducing the growing incidence and impact of osteoporosis. Medical students had higher scores possibly due to better training programs.  The lack of KAP can have a serious and growing impact on the health sector and patients’ health in terms of cost, healthcare resources, and social impact. Nurses and medical students can play a valuable role in educating patients on bone fractures/osteoporosis, its risks, and prevention, as well as in helping them with nutrition, drug and lifestyle recommendations.
Biography:
Abhaya Gupta trained in India then moved abroad after his postgraduate MD degree. He has extensive experience of managing acute medical and elderly Medicine issues at hospitals in India, Middle East and UK. He  is currently  working as Consultant Medicine and Care of Elderly since last 20 years at a teaching hospital in United Kingdom. He is a teacher and trainer for junior doctors/ nursing and multidisciplinary team members,  examiner for Cardiff Medical School . He also is practising  Acute Clinical Physician in hospital. He  has specialist expertise and experience in Orthogeriatrics. He  commenced and leads specialist osteoporosis service at UK hospital, had first patient on Injection Romosozumab in Wales. He was a pioneer at commencing Acute Collaborative Orthogeriatrician led Acute Hip Unit since 2011 for patients with Hip Fractures- first of its kind in Wales,UK  - a unique award winning service. He is Editorial Board member of ‘Geriatric Medicine’ , reviewer of ‘Age and Ageing’ journal and member of local specialist societies. He has published widely in several peer reviewed journals, and presented his research as posters at several national and International meetings and conferences. He has published a book ‘Measurement scales in Elderly Medicine’. He is a member of GOSI (Geriatric Orthopaedic Society of India) and has been invited as speaker at GOSICON and GERICON conferences. His main hobby is helping his Psychiatrist wife in house gardening jobs
Abstract:
Objectives: Vitamin D deficiency is defined as a risk factor for osteoporotic fractures but  the prevalence in the subgroup of frail older hospitalized patients is not clear. We sought to investigate the prevalence and predictors of vitamin D deficiency in frail older hospitalized patients.
The aim of this study was to evaluate serum levels of 25-hydroxyvitamin D (25OHD) in high fracture risk hospitalised patients with or without fragility fractures
 Methods: we measured the serum 25OHD levels of 45 patients admitted with vertebral fractures, 87 patients with hip fractures, 35 patients with Parkinsons disease , 220 patients with frailty to evaluate the prevalence of vitamin D insufficiency. Those who were receiving antiosteoporosis therapy including vitamin D  were excluded.  Serum 25 (OH)D concentrations < 29.9 nmol/L and between 30 and 49.99 nmol/L were classified as deficient and insufficient, respectively, whereas concentrations ?50 nmol/L were considered as desirable. A stepwise binary logistic regression model was performed to assess the simultaneous effects of age, gender and comorbidities on the prevalence of  low vitamin D concentration.
Results: Mean age of the cohort was 83.6±8.0 years (72% females)  only 5% had desirable serum concentrations ?50 nmol/L , 25% had concentrations in insufficiency range 70% were in deficiency range. Vitamin D deficiency and insufficiency was prevalent in high fracture risk patients (71%) and more common in female patients (78%). Univariate logistic regression analysis showed age, gender, bone mass index (BMI), femoral neck BMD, calcium, and vitamin D levels were significantly different between patients with fragility fractures and the control group. 25OHD levels was not significantly associated with their underlying diseases, such as diabetes mellitus, hypertension or stage of chronic kidney disease but were significantly lower in patients with recurrent falls and frailty. The other markers, albumin, alkaline phosphatase, PTH were not significantly associated with 25OHD levels.
Conclusion: In the group of frail older hospitalized patients without previous vitamin D supplementation, the prevalence of inadequate vitamin D concentrations is extremely high.  Vitamin D insufficiency is likely to be an important risk factor for fragility fractures  as well as patients with recurrent falls and frailty in both men and women but more pronounced in females. Therefore, usefulness of the routine measurement of vitamin D status before initiating of supplementation appears to be questionable in this patient group. Further studies to evaluate possible routine supplementation of Vitamin D (simple and cheap intervention) to derive its benefits in this high risk group is needed.
Biography:
Dr. Wane has a PhD in Nursing Science as well as a master’s degree from the University of South Florida and is a Board-Certified Family Nurse Practitioner. She also has undergraduate degrees in Nutrition and Nursing from Brooklyn College and Downstate Medical Center College of Nursing. After 32 years, Dr. Wane has retired from PHSC and now is focused on the role of Nurse Consultant. She has published numerous supplements in textbooks as well as journal articles, continues to serve as an editorial board member and peer reviewer for several journal publications. She is also a member of Sigma Theta Tau Nursing Honor Society and a CCNE evaluator.

Abstract:
Statement of the Problem: With the advent of technology and the advancement of the Electronic Health Record (EHR), clinical communication interactions have been impacted leading to a detached relationship between stakeholders in the clinical practice setting (Patients, nurses, physicians, staff and family). Too often, there is a detached sense of reality in the clinical practice setting whereby the skill/technology becomes the focus of the interaction and the patient/family gets lost in the process.
Methodology & Theoretical Orientation: Real world examples will be reviewed and analyzed for their relative contribution. Using EBP resources and a common-sense approach, strategies will be discussed that will hopefully improve clinical communication interactions in the practice setting. Findings: The value of placing “humanity and compassion” back at the bedside will lead to improved outcomes in healthcare whereby the clinical communication interaction is utilized rather than excluded due to technological advances. Clinical judgment and clinical decision-making often are lost as the technological focus overrides the responsibility and accountability to make accurate assessments based on clinical data. The cornerstone of “what if,” “why” and “how” are not being addressed in a timely manner leading to crisis clinical management rather than preventative management.
Recommendations Bringing back respect into the clinical communication interactions will help facilitate improved outcomes and valued relationships in the practice setting. Use communication techniques at the bedside and maintain an open dialogue whereby data is observed , recorded and analyzed in a real time rather than as an historical event. Enabling the nurse at the bedside to seek answers and analyze rather than      react as a  data entry point of contact will help  facilitate outcomes. 
Biography:
Dr. Kotb Abdelmohsen is a senior associate scientist at the NIH's National Institute on Aging (NIA), specializing in cellular senescence, aging, and molecular biology. With over two decades of research experience, Dr. Abdelmohsen has contributed significantly to understanding the mechanisms of aging and age-related diseases. His talk will focus on senescence-associated secretory phenotypes (SASP), extracellular vesicles (EVs), and their potential therapeutic applications.

Abstract:
Cellular senescence, a state of irreversible cell cycle arrest, plays a pivotal role in aging and age-related disorders. Understanding senescence and identifying novel therapeutic strategies are critical for mitigating its pathological effects. In this study, we investigated the secretome and extracellular vesicles (EVs) derived from human trophoblast stem cells (hTSCs) for their potential anti-senescence properties. We found that the hTSC-S and EVs significantly suppressed the expression of key SASP-related mRNAs, including CXCL1, CXCL8, and GDF15. We found that the hTSC-S and EVPs are enriched in proteins involved in extracellular matrix remodeling, cell adhesion, and tissue repair, underscoring their anti-inflammatory impacts. The hTSC-S effectively reduced both the expression of SASP-related mRNAs and the secretion of their encoded proteins. These effects may be linked to decreased senescence-associated ?-galactosidase (SA-?-Gal) activity and reduced DNA damage. Furthermore, hTSC-S attenuated inflammatory signaling by inhibiting NF-?B phosphorylation, a major SASP regulator. In vivo analysis indicated that hTSC-S treatment decreased the levels of the pro-inflammatory marker CXCL1 and the aging marker GDF15. Our findings establish hTSC-S and EVs as promising candidates for senescence-targeted therapies, offering a novel strategy to address aging and age-related diseases.
Biography:
Dr. Arati Kiran Kanchi is a physician by training. She has been part of the pharmaceutical/CRO industry contributing to the drug development in various indications like Diabetes, oncology, autoimmune diseases for the last 10 years. Currently she serves as medical director at a biotechnology company called Amgen. In recent years, she has been working on drug development for the rare diseases and led multiple early as well as late phase clinical trials in the rare disease patient population. Her passion to serve the patients with serious conditions and unmet needs drives her to find solutions to the research needs despite the ongoing challenges every day.
Abstract:
Rare disease is a disease or condition that affects less than 200,000 people in the United States. An orphan drug is a drug for a rare disease or condition. Over 7000 rare diseases affect an estimated 25-30 million people with a rare disease in the U.S. Many conditions are serious and life threatening, however, most of them lack the effective and approved treatment options. Hence, the clinical trials in the rare diseases are of critical importance to develop new therapies for treatment of these diseases. Recruitment of rare disease patient population in the clinical trials remains a huge challenge. Considerable number of clinical trials delay or fail due to difficulties in recruiting the patients. This systemic review addresses the common barriers in enrolling the patients in the clinical trials and potential measures which can help to improve the recruitment, based on existing literature analysis and lessons learned from the clinical study conduct. The challenges remain with the rare nature of the disease, complexities of the trial design, regulatory approval pathways, need of deep expertise and understanding of the diseases. Increasing competition between sponsor companies has also boosted the recruitment difficulties of the rare disease trials. Maximizing collaborative efforts with the appropriate stakeholders can be a key to overcome these challenges and boost the recruitment of patients with rare disease in the clinical trials. This review will also identify and discuss other potential solutions like innovative trial designs, patient enrichment, patient centric recruitment strategies, effective partnerships with the patient groups.
Young Research Forum
Biography:
Mihaela Diana Stanica  graduate of the University of Pitesti, Faculty of General Nursing. She is currently a PhD student at the "Carol Davila" University of Medicine and Pharmacy.2016- 2020  General medical assistant within a private company specializing in home care and palliative care.2020 -present General medical assistant specializing in Radiology within the Pitesti County Emergency Hospital, Radiology and Medical Imaging department.

Abstract:
Effective communication between nurses and patients is essential for the provision of quality healthcare services. Despite its importance, the communication process frequently encounters barriers that can affect patient care outcomes. The present study aims to identify and analyze current barriers in the communication process between nurses and patients, highlighting the latest research and solutions to overcome them.Effective communication is an essential component of healthcare, having a significant impact on the quality of care, patient safety and the well-being of healthcare professionals. According to the World Health Organization (WHO), communication errors are one of the leading causes of medical errors that can endanger patient safety.The current state of knowledge regarding communication barriers in the nursing process indicates that they significantly impact patient safety, treatment effectiveness, and interprofessional collaboration.According to the specialized literature, communication barriers in the nursing process are defined as any obstacle that limits the ability to send, receive, and correctly interpret messages. These barriers negatively affect the nurse-patient relationship, collaboration between members of the medical team, and the efficiency of the medical act.Recent research has highlighted the importance of targeted interventions to reduce communication barriers in nursing.Management communication barriers in nursing is essential for ensuring of a care safe , efficient and patient -focused . By using communication methods standardized (SBAR), training SKILLS intercultural and development protocols institutional , it can provide a working environment efficient and harmonious .